Search 

DIGNA Biotech is a private biotechnology company headquartered in Pamplona (Spain), with offices in Madrid and Pennsylvania (USA). It was founded in 2004 as a spin-off of the University of Navarra. The firm currently has a pipeline of 9 products at different stages of development in 3 therapeutic areas: Inflammatory/Autoimmune, Cardiovascular and Liver diseases.

 Digna Biotech is seeking private funding to spin out a new biotech company to conduct Phase IIb and Phase III trials of its more advanced candidate, a cytokine inhibitor for the treatment of patients with Systemic Sclerosis and Localized Scleroderma. The product (Disitertide) has already completed Phase I, Phase IIa and open-label extension (OLE) clinical trials under a topical formulation in patients with systemic sclerosis. Orphan drug designation by both FDA and EMA has been granted in the two indications.

Ennar Pharma was founded in July 2010 to develop a better and safer topical treatment for mild-to-moderate psoriasis. Patents, protecting the technology, have been granted in Europe and the USA. The company is financially supported by an investment by EVA- a Basel based venture capital company- and uses a network of strategic partners to develop the production of EGF and develop a suitable cream-based pharmaceutical product. Producers for the cGMP production of high-quality EGF(epidermal growth factor) and for a stable cream formulation of the active ingredient have been contracted and a Proof-of-Concept trial is running at the Dermatology Clinic of the University of Zurich. The trial, which is carried out with mild-to-moderate psoriasis patients, aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulation and test an optimised formulation for clinical efficacy and safety. Results of the trial are expected in Q1 2013.

SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline.

During the last 34 months we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover clear medical need indications:

SOM0777 for the treatment of Glioma, already licensed to Argon Pharma and Draconis Pharma.

SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 1Q 2013.

SOM0606 for the topical treatment of Psoriasis, in preclinical development. Phase II expected for 4Q 2013.

25 more repurposing programs per year are running to file the advanced company pipeline.